Esperion Therapeutics Earlier Reported Q2 EPS $(2.01) Misses $(1.86) Estimate, Sales $982K Beat $930K Estimate; Expects Full-Year 2019 Net Increase In Cash Of Approximately $90 To $100 Million
Benzinga_Newsdesk